-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------
20.12.2007
Erlangen, 20 December 2007. The Hamburg based IBL Gesellschaft für Immunchemie und Immunbiologie mbH, a 100% subsidiary of the Erlangen based development and holding company november AG (ISIN DE000A0S9N72) has filed for insolvency today, 20 December 2007, with the local court of Hamburg because of illiquidity and on-balance sheet over-indebtedness. This is because the ongoing negotiations with different banks relating to different loans could not be concluded in time before the expiry of the insolvency deadline.
end of announcement euro adhoc --------------------------------------------------------------------------------
ots Originaltext: november AG Im Internet recherchierbar: http://www.presseportal.de
Further inquiry note:
Marcus Weichert
november AG - Public Relations/Investor Relations
Ulrich-Schalk-Str. 3, D-91056 Erlangen
Tel.: +49 (0)9131 750 88 868
e-mail: weichert@november.de, www.november.de
Branche: Biotechnology ISIN: DE000A0S9N72 WKN: A0S9N7 Index: CDAX, Prime All Share, Technologie All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Stuttgart / free trade Börse Düsseldorf / free trade Börse Hannover / free trade Börse München / free trade